Literature DB >> 22550156

Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.

Gregg F Rosner1, Ajay J Kirtane, Philippe Genereux, Alexandra J Lansky, Ecaterina Cristea, Bernard J Gersh, Giora Weisz, Helen Parise, Martin Fahy, Roxana Mehran, Gregg W Stone.   

Abstract

BACKGROUND: The clinical significance of incomplete coronary revascularization (ICR) after percutaneous coronary intervention in patients with acute coronary syndromes is unknown. METHODS AND
RESULTS: We performed quantitative angiography of the entire coronary tree in 2954 patients with acute coronary syndromes in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. ICR was variably defined if any lesion with diameter stenosis (DS) cutoffs ranging from ≥30% to ≥70% with reference vessel diameter ≥2.0 mm remained after percutaneous coronary intervention. The primary outcome was 1-year composite rate of major adverse cardiac events (death, myocardial infarction, or ischemia-driven unplanned revascularization). With the use of DS cutoffs ≥30%, ≥40%, ≥50%, ≥60%, and ≥70%, the prevalence of ICR after percutaneous coronary intervention was 75%, 55%, 37%, 25%, and 17%, respectively. The 1-year major adverse cardiac event rate was increased among patients with ICR using all of the DS cutoffs. ICR (≥50% DS) was associated with higher 1-year rates of myocardial infarction (12.0% versus 8.2%; hazard ratio, 1.50; 95% confidence interval, 1.18-1.89; P=0.0007) and ischemia-driven unplanned revascularization (15.7% versus 10.2%; hazard ratio, 1.58; 95% confidence interval, 1.28-1.96; P<0.0001), with a trend toward increased mortality (3.1% versus 2.2%; hazard ratio, 1.43; 95% confidence interval, 0.90-2.27; P=0.13). By multivariable analysis, ICR (≥50% DS) was an independent predictor of 1-year major adverse cardiac events (hazard ratio, 1.36; 95% confidence interval, 1.12-1.64; P=0.002). The impact of ICR on major adverse cardiac events was similar regardless of chronic total occlusion presence, but it was more pronounced with a greater number of nonrevascularized lesions.
CONCLUSIONS: Depending on the threshold of percent DS, ICR was present in 17% to 75% of patients with acute coronary syndromes after percutaneous coronary intervention. Regardless of the threshold, ICR was strongly associated with 1-year myocardial infarction, ischemia-driven unplanned revascularization, and major adverse cardiac events. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00093158.

Entities:  

Mesh:

Year:  2012        PMID: 22550156     DOI: 10.1161/CIRCULATIONAHA.111.069237

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

Review 1.  Appropriateness of percutaneous coronary intervention: a review.

Authors:  Matthew R Summers; Manesh R Patel
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

2.  Prognostic superiority of coronary artery bypass grafting to percutaneous coronary intervention in non-diabetic patients with anatomically complex multivessel coronary artery disease.

Authors:  Kenji Sakata; Takuya Nakahashi; Masa-Aki Kawashiri
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

Review 3.  Complete versus incomplete coronary revascularization: definitions, assessment and outcomes.

Authors:  Prakriti Gaba; Bernard J Gersh; Ziad A Ali; Jeffrey W Moses; Gregg W Stone
Journal:  Nat Rev Cardiol       Date:  2020-10-16       Impact factor: 32.419

4.  The relationship between revascularization extent and the long-term prognosis of patients with stable angina pectoris and three-vessel disease treated by percutaneous coronary intervention in the era of drug-eluting stents.

Authors:  Quan Li; Xianpeng Yu; Jiqiang He; Yuechun Gao; Xiaoling Zhang; Changyan Wu; Yawei Luo; Yuchen Zhang; Xuejun Ren; Shuzheng Lv; Fang Chen
Journal:  Clin Cardiol       Date:  2014-08-14       Impact factor: 2.882

Review 5.  Experimental and early investigational drugs for angina pectoris.

Authors:  Islam Y Elgendy; David E Winchester; Carl J Pepine
Journal:  Expert Opin Investig Drugs       Date:  2016-11-14       Impact factor: 6.206

6.  Association of Coronary Vessel Characteristics With Outcome in Patients With Percutaneous Coronary Interventions With Incomplete Revascularization.

Authors:  Edward L Hannan; Ye Zhong; Peter B Berger; Alice K Jacobs; Gary Walford; Frederick S K Ling; Ferdinand J Venditti; Spencer B King
Journal:  JAMA Cardiol       Date:  2018-02-01       Impact factor: 14.676

7.  Complete revascularization determined by myocardial perfusion imaging could improve the outcomes of patients with stable coronary artery disease, compared with incomplete revascularization and no revascularization.

Authors:  Jiehui Li; Xiubin Yang; Yueqin Tian; Hongxing Wei; Marcus Hacker; Xiang Li; Xiaoli Zhang
Journal:  J Nucl Cardiol       Date:  2017-12-06       Impact factor: 5.952

8.  Trends in myocardial infarction rates and case fatality by anatomical location in four United States communities, 1987 to 2008 (from the Atherosclerosis Risk in Communities Study).

Authors:  Jonathan D Newman; Daichi Shimbo; Chris Baggett; Xiaoxi Liu; Richard Crow; Joellyn M Abraham; Laura R Loehr; Lisa M Wruck; Aaron R Folsom; Wayne D Rosamond
Journal:  Am J Cardiol       Date:  2013-09-21       Impact factor: 2.778

9.  Incomplete revascularization is associated with greater risk of long-term mortality after stenting in the era of first generation drug-eluting stents.

Authors:  Chuntao Wu; Anne-Marie Dyer; Gary Walford; David R Holmes; Spencer B King; Nicholas J Stamato; Samin Sharma; Alice K Jacobs; Ferdinand J Venditti; Edward L Hannan
Journal:  Am J Cardiol       Date:  2013-06-04       Impact factor: 2.778

10.  Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial.

Authors:  Colin Berry; Jamie Layland; Arvind Sood; Nick P Curzen; Kanarath P Balachandran; Raj Das; Shahid Junejo; Robert A Henderson; Andrew H Briggs; Ian Ford; Keith G Oldroyd
Journal:  Am Heart J       Date:  2013-08-27       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.